share_log

Merck & Co | 4: Statement of changes in beneficial ownership of securities-Officer Li Dean Y

默沙東 | 4：持股變動聲明-高管 Li Dean Y

SEC announcement ·  01/25 05:15
牛牛AI助理已提取核心訊息
Li Dean Y, Executive VP & President of Merck & Co.'s MRL division, completed a purchase of 25,760 shares of the company's common stock on January 22, 2024. The transaction was carried out directly with the shares acquired at a price of $119.43 each. Following this acquisition, Li's total direct holdings in Merck & Co. amount to 46,242.37 shares. The transaction, which is categorized as a grant, award, or other acquisition, reflects a significant investment in the company by one of its top executives.
Li Dean Y, Executive VP & President of Merck & Co.'s MRL division, completed a purchase of 25,760 shares of the company's common stock on January 22, 2024. The transaction was carried out directly with the shares acquired at a price of $119.43 each. Following this acquisition, Li's total direct holdings in Merck & Co. amount to 46,242.37 shares. The transaction, which is categorized as a grant, award, or other acquisition, reflects a significant investment in the company by one of its top executives.
默沙東執行副總裁兼總裁李迪安 Y其MRL部門於2024年1月22日完成了對公司25,760股普通股的購買。該交易是直接以每股119.43美元的價格收購的股票進行的。此次收購後，李在默沙東的直接持股總額爲46,242.37股。該交易被歸類爲贈款、獎勵或其他收購，反映了該公司的一位高管對公司的重大投資。
默沙東執行副總裁兼總裁李迪安 Y其MRL部門於2024年1月22日完成了對公司25,760股普通股的購買。該交易是直接以每股119.43美元的價格收購的股票進行的。此次收購後，李在默沙東的直接持股總額爲46,242.37股。該交易被歸類爲贈款、獎勵或其他收購，反映了該公司的一位高管對公司的重大投資。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。